Cosmetic Label Claims, OTC Drug Classification, and Import Risk

Introduction

Foreign beauty and personal-care brands usually discover the hard part of U.S. compliance at the label stage, not at registration. A product that looks like a cosmetic in its formula or packaging can still be regulated as a drug if its label, website, or marketing materials communicate disease treatment, prevention, or structure/function effects rather than appearance-focused use. FDA

That distinction matters because facility registration, product listing, or U.S. Agent designation do not fix a classification problem. If the intended use expressed through claims pushes the product into drug territory, the product has to meet drug rules, not cosmetic rules, and import scrutiny can follow when the label and the regulatory posture do not match. FDA

This page is for foreign skincare, haircare, fragrance, soap, and personal-care brands reviewing U.S. labels before launch, especially teams without in-house U.S. regulatory staff. The practical question is not just “what must appear on the label,” but “what does this label cause FDA to think the product is?”

What this review is meant to catch

• Claims that shift a product from cosmetic positioning into drug positioning
• Missing or weak mandatory label elements such as identity, net contents, ingredient declaration, warnings, and responsible-party information
• Places where product listing or facility registration is being treated as a substitute for claim and label compliance
• Import-risk signals that can draw attention at the border even before a deeper enforcement action

The classification decision starts with intended use

Under the FD&C Act, cosmetics are products intended for cleansing, beautifying, promoting attractiveness, or altering appearance. Drugs include products intended for diagnosing, curing, mitigating, treating, or preventing disease, and products intended to affect the structure or any function of the body. A single product can be both, but once drug claims are present, cosmetic-only compliance is no longer enough. FDA

A useful way to think about it: appearance claims usually stay on the cosmetic side; physiological claims change the regulatory burden. “Makes skin look smoother” is a different regulatory signal from “stimulates collagen,” “repairs the skin barrier,” or “treats acne.” The words may feel close in marketing, but they do not land the same way with FDA. FDA

Claims that usually fit cosmetic positioning

• Cleanses skin or hair
• Moisturizes or softens
• Adds shine, fragrance, color, or a smoother appearance
• Improves the look of fine lines or uneven tone without implying treatment

Claims that often trigger drug analysis

• Treats or prevents acne, eczema, dandruff, rosacea, fungal conditions, or irritation
• Heals, repairs, restores, regenerates, or reverses a medical or physiological condition
• Stimulates collagen, changes skin structure, affects inflammation, or alters body function
• Provides sun protection, SPF, or other therapeutic skin-protection claims

FDA also looks beyond the front label. Product names, website copy, social posts, before-and-after framing, and ingredient storytelling can all contribute to intended use. That is why brands sometimes think they have a cosmetic label problem when they actually have a broader claims architecture problem.

Named product routes: cosmetic, OTC monograph drug, combination, or NDA

The product name alone does not determine the route. The intended-use claim, active ingredients, concentration, dosage form, directions, warnings, labeling, and required testing must fit the governing framework. The table below resolves the categories foreign beauty and personal-care brands most often export.

Monograph compliance versus an NDA

An OTC monograph is a category-wide standard for permitted active ingredients, strengths, dosage forms, uses, labeling, testing, and other conditions. The CARES Act moved OTC monograph development and amendment from notice-and-comment rulemaking to an administrative-order process under section 505G. A product that conforms to the applicable monograph and other drug requirements may be marketed without an approved drug application, but it is not thereby “FDA approved.” FDA OTC Drug Review

An NDA is product-specific premarket approval. A nonprescription drug that falls outside the applicable monograph cannot be legalized merely by registering the facility, obtaining an NDC, or submitting a drug listing. The sponsor needs an approved NDA or ANDA, as applicable, unless FDA first changes the monograph through the administrative-order process. FDA OTC market-entry guidance

What a foreign monograph drug manufacturer still has to file

• Complete drug establishment registration by SPL before offering the drug for import, identify the U.S. Agent and known importers, and renew the registration between October 1 and December 31 every year. FDA drug establishment registration instructions
• Obtain a labeler code and list each drug with its NDC information and current labeling through a drug-listing SPL. Listings must be updated after changes, and unchanged listings require annual certification. FDA drug-listing instructions
• Comply with drug CGMP and OTC labeling requirements. A sunscreen moisturizer, acne cleanser, anti-dandruff shampoo, or antiperspirant-deodorant must also meet applicable cosmetic obligations because it is both a drug and a cosmetic. FDA importing OTC drugs guidance

Category examples buyers should pressure-test before launch

These examples are not definitive classifications for any specific product. They show where foreign brands most often drift across the line.

Skincare

“Hydrates,” “brightens the look of skin,” and “improves the appearance of texture” are usually cosmetic-style claims. “Treats acne,” “reduces inflammation,” “rebuilds collagen,” or “repairs damaged skin cells” move toward drug positioning. Anti-aging language is especially sensitive when it implies structural change rather than visible appearance. FDA

Haircare

Shampoo, conditioner, styling, shine, and cosmetic appearance claims are one lane. Anti-dandruff, hair-growth, hair-loss, scalp-treatment, or therapeutic scalp-condition claims are another. FDA specifically identifies dandruff and hair restoration claims as examples that can make a product a drug or both a drug and a cosmetic. FDA

Fragrance and personal care

Perfume, deodorizing, and scent claims are usually cosmetic territory. Claims about stress relief, hormone effects, antimicrobial treatment, or symptom relief can create a different classification analysis depending on how they are presented and what intended use they imply.

Soap

“Soap” is a recurring confusion point because some products marketed as soap are regulated as cosmetics, and some traditional soap products may fall outside cosmetic regulation depending on composition and intended use. Once the product is marketed with moisturizing, deodorizing, exfoliating, acne, or other cosmetic or therapeutic claims, the exemption logic usually gets weaker fast. FDA

What belongs in a serious U.S. label review

A label review that only checks whether the facility is registered misses the point. The stronger review asks whether the product identity, mandatory disclosures, and claims all tell a consistent regulatory story.

FDA labeling summary

Where INCI, identity, warnings, net contents, and responsible-party details fit

For cosmetics, FDA’s labeling framework centers on a few mandatory elements that need to be present, conspicuous, and internally consistent. The identity statement tells consumers what the product is. The net quantity declaration belongs on the principal display panel. Ingredient declarations generally must use common or usual names and appear in descending order of predominance for retail cosmetics. FDA Cosmetics Labeling Guide

MoCRA added another layer: the responsible person must ensure and maintain records supporting adequate safety substantiation, and cosmetic labels now need responsible-party contact information. That role is not the same as the foreign facility’s U.S. Agent. For foreign brands, that distinction matters because a valid U.S. Agent designation does not satisfy responsible-person labeling obligations by itself. FDA MoCRA

FDA Entry Point’s cosmetic label review service is built around these execution points: INCI verification, MoCRA label checks, claims review, and mandatory elements such as net quantity, country-of-origin handling, and manufacturer or distributor statements. For brands entering the U.S. for the first time, that is usually the more practical workflow than treating label review as a last-minute design edit. FDA Entry Point

Claim substantiation is part of the label risk, not a separate project

One pattern worth naming: brands often separate “copy approval” from “evidence,” but FDA does not. If a claim implies a product effect, the company should be able to support that claim with competent substantiation and maintain safety support appropriate to the product. Under MoCRA, the responsible person must maintain records supporting adequate safety substantiation for cosmetic products. FDA Voices

That does not mean every cosmetic claim requires drug-style clinical evidence. It does mean the company should know what evidence supports each meaningful claim, what testing or documentation exists, and whether the claim language overstates what the evidence actually shows. “Clinically proven to treat acne” and “helps skin look clearer” are not just different marketing choices; they imply different regulatory expectations.

How label problems become import problems

Import risk usually starts with appearance of violation, not with a full merits debate. FDA can refuse imported products that appear to violate the law, and import alerts can lead to detention without physical examination for affected products or firms. Cosmetics marketed with therapeutic claims, mislabeled products, and products with other compliance defects can all draw scrutiny. FDA Import Alerts

For cosmetics specifically, FDA notes that labels or labeling with disease or structure/function claims can cause a product to be considered a drug. That matters at the border because the shipment may be arriving as a cosmetic while the claims suggest a different regulatory category. Registration and listing data do not cure that mismatch. FDA importing cosmetics

An imported moisturizer with SPF, acne cleanser, anti-dandruff shampoo, antiperspirant-deodorant, or hand sanitizer creates an additional records test. FDA verifies drug establishment registration, drug listing, application or monograph status, labeling, and other applicable requirements against entry data. A product declared as a cosmetic while its claims and records identify an OTC drug can be detained while FDA gathers more information, and a drug that requires an application but lacks one is subject to refusal. FDA importing human drugs

In practice, the first cracks often show up as customs questions, FDA holds, requests for clarification, or broader concern about whether the importer understands the product’s regulatory status. For foreign brands, that is why pre-launch label review is usually cheaper than post-arrival correction.

FDA Entry Point is a strong fit when label review needs to connect to filing and market-entry work

Some providers only act as the U.S. Agent of record. FDA Entry Point is set up for brands that need the label, claims, registration, listing, and ongoing contact pieces to work together under one relationship across cosmetics, food, drugs, and devices. FDA Entry Point connects cosmetic label review to INCI checks, MoCRA requirements, and cosmetic-versus-drug claim analysis rather than treating the U.S. Agent role as a mailbox-only service. FDA Entry Point

That is most relevant for foreign skincare, haircare, and personal-care brands that are still deciding how a product should be positioned in the U.S., or that have already learned that listing a product does not solve a claims problem. It is less about buying a name on a form and more about reducing the chance that the label creates the wrong regulatory category in the first place.

Foreign brands can coordinate the separate filing tracks through FDA Entry Point’s MoCRA cosmetic registration support and drug registration and SPL support.

Common pitfalls before launch

• Assuming MoCRA registration or product listing makes aggressive claims acceptable
• Assuming OTC monograph compliance means the product is FDA approved or exempt from drug registration and listing
• Using the withdrawn COVID-19 temporary hand sanitizer guidance as the current route to market
• Reviewing the carton but not the website, marketplace copy, or social ads that also shape intended use
• Using “natural,” “organic,” or “clean” as if FDA had pre-approved definitions for cosmetic marketing claims
• Confusing the U.S. Agent with the Responsible Person on cosmetic labels
• Borrowing claims from another market where the same wording sits in a different regulatory category

Frequently asked questions

Does my sunscreen need FDA approval or just monograph compliance?

A sunscreen that fully conforms to current OTC Monograph M020 can be marketed without an approved NDA, but monograph compliance is not the only obligation. SPF and sunburn-prevention claims make the product a drug, while a moisturizer or makeup product with SPF is both a cosmetic and a drug. Foreign manufacturers still need drug establishment registration, listing, SPL submissions, compliant labeling, and CGMP. A product outside M020 may require an approved application or a change to the monograph. FDA sunscreen framework

What FDA rules apply to importing hand sanitizer into the U.S.?

Hand sanitizer is imported as an OTC drug, not a cosmetic. A conforming consumer antiseptic rub can be marketed without an approved NDA, but the foreign manufacturer must register its drug establishment before import, identify its U.S. Agent and importers, list the product with NDC information through SPL, follow drug CGMP, and use compliant OTC drug labeling. The temporary COVID-19 manufacturing guidance no longer provides a separate market route. FDA importing OTC drugs guidance

Can I sell an acne treatment cream in the U.S. without an NDA?

Yes, an acne treatment cream can be marketed without an approved NDA when it fully conforms to OTC Monograph M006 and all other applicable drug requirements. The active ingredient, concentration, dosage form, indications, directions, warnings, and labeling must fit the monograph. A cleanser or moisturizer carrying an acne-treatment claim is also a cosmetic-drug combination and must satisfy cosmetic obligations. A nonconforming product needs an approved application or an FDA monograph change before marketing. FDA OTC Monograph M006

What is the difference between an OTC monograph drug and a New Drug Application?

An OTC monograph is a category-wide standard, while an NDA is product-specific premarket approval. A drug that meets every applicable monograph condition can be marketed without an approved NDA, although the manufacturer must still complete registration, listing, labeling, and manufacturing requirements. An NDA requires FDA to review and approve the individual product before marketing. Products outside an applicable monograph cannot use registration or an NDC as a substitute for that approval. FDA nonprescription drug application process

Can I label my cosmetics “natural” or “organic” without FDA approval?

Yes, but those words do not exempt a cosmetic from FDA labeling rules or from the need for truthful, supportable claims. FDA does not preapprove cosmetic products or most cosmetic label claims before sale, and “natural” or “organic” language does not solve problems with identity, ingredients, warnings, or drug-like intended use. Organic claims can also raise separate USDA requirements, while advertising claims remain subject to FTC standards. Natural and organic cosmetic claims guide

Can my U.S. Agent also act as my MoCRA Responsible Person?

The same provider can support both functions only when the separate requirements for each role are satisfied. The U.S. Agent is the FDA contact tied to a foreign facility, while the Responsible Person is the manufacturer, packer, or distributor named on the cosmetic label and responsible for the product listing. Using one provider does not merge the roles, so the label, facility registration, and product listing must each identify the correct party. MoCRA Responsible Person and U.S. Agent guide

References

• FDA: Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)
• FDA: Cosmetics Labeling Claims
• FDA: Summary of Cosmetics Labeling Requirements
• FDA: Modernization of Cosmetics Regulation Act of 2022
• FDA: OTC Drug Review Process and Monographs
• FDA: OTC Monograph M020 and Sunscreen Regulatory Actions
• FDA: OTC Monograph M006 for Topical Acne Drugs
• FDA: OTC Monograph M032 for Dandruff, Seborrheic Dermatitis, and Psoriasis
• FDA: OTC Monograph M019 for Antiperspirants
• FDA: Withdrawal of Temporary Hand Sanitizer Guidances
• FDA: OTC Skin-Lightening Products
• FDA: Importing Over-the-Counter Drugs
• FDA: Import Alerts
• FDA Entry Point: Cosmetic Label Review, INCI, and Claims
• FDA Entry Point: Cosmetic Registration and MoCRA Support
• FDA Entry Point: Drug Registration and SPL Support